NASDAQ:GERN - Geron Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.50 -0.01 (-0.18 %)
(As of 09/20/2018 04:00 PM ET)
Previous Close$5.51
Today's Range$5.41 - $5.54
52-Week Range$1.74 - $6.99
Volume4.00 million shs
Average Volume5.80 million shs
Market Capitalization$1.01 billion
P/E Ratio-30.33
Dividend YieldN/A
Beta3.13
Geron logoGeron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.

Receive GERN News and Ratings via Email

Sign-up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:GERN
CUSIP37416310
Phone650-473-7700

Debt

Debt-to-Equity RatioN/A
Current Ratio33.12
Quick Ratio33.12

Price-To-Earnings

Trailing P/E Ratio-30.33
Forward P/E Ratio14.10
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.07 million
Price / Sales943.84
Cash FlowN/A
Price / CashN/A
Book Value$0.65 per share
Price / Book8.46

Profitability

EPS (Most Recent Fiscal Year)($0.18)
Net Income$-27,910,000.00
Net Margins-3,232.73%
Return on Equity-23.15%
Return on Assets-22.17%

Miscellaneous

Employees18
Outstanding Shares183,620,000
Market Cap$1.01 billion

Geron (NASDAQ:GERN) Frequently Asked Questions

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) posted its quarterly earnings data on Tuesday, July, 31st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.04). The biopharmaceutical company had revenue of $0.21 million for the quarter, compared to analysts' expectations of $0.21 million. Geron had a negative net margin of 3,232.73% and a negative return on equity of 23.15%. View Geron's Earnings History.

When is Geron's next earnings date?

Geron is scheduled to release their next quarterly earnings announcement on Wednesday, November, 7th 2018. View Earnings Estimates for Geron.

What price target have analysts set for GERN?

5 analysts have issued 1-year price objectives for Geron's stock. Their forecasts range from $4.00 to $7.00. On average, they anticipate Geron's stock price to reach $5.5833 in the next year. This suggests a possible upside of 1.5% from the stock's current price. View Analyst Price Targets for Geron.

What is the consensus analysts' recommendation for Geron?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Geron.

Are investors shorting Geron?

Geron saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 62,898,757 shares, an increase of 5.2% from the August 15th total of 59,807,261 shares. Based on an average daily volume of 9,511,669 shares, the days-to-cover ratio is currently 6.6 days. Currently, 34.4% of the shares of the stock are sold short. View Geron's Current Options Chain.

Who are some of Geron's key competitors?

Who are Geron's key executives?

Geron's management team includes the folowing people:
  • Dr. John A. Scarlett, CEO, Pres & Director (Age 67)
  • Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 49)
  • Dr. Andrew J. Grethlein, Exec. VP of Devel. & Technical Operations (Age 54)
  • Mr. Stephen N. Rosenfield, Exec. VP, Gen. Counsel & Corp. Sec. (Age 68)
  • Ms. Melissa A. Kelly Behrs, Exec. VP of Bus. Devel., Portfolio & Alliance Management (Age 54)

Has Geron been receiving favorable news coverage?

Media headlines about GERN stock have trended somewhat positive recently, according to Accern. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Geron earned a coverage optimism score of 0.18 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for Geron.

Who are Geron's major shareholders?

Geron's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (8.48%), BlackRock Inc. (7.29%), Northern Trust Corp (1.08%), Bank of America Corp DE (0.68%), Schwab Charles Investment Management Inc. (0.19%) and Creative Planning (0.18%). Company insiders that own Geron stock include Robert J Spiegel and Stephen Rosenfield. View Institutional Ownership Trends for Geron.

Which major investors are selling Geron stock?

GERN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC. Company insiders that have sold Geron company stock in the last year include Robert J Spiegel and Stephen Rosenfield. View Insider Buying and Selling for Geron.

Which major investors are buying Geron stock?

GERN stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of America Corp DE, Northern Trust Corp, California Public Employees Retirement System, Creative Planning, Schwab Charles Investment Management Inc., SG Americas Securities LLC and MetLife Investment Advisors LLC. View Insider Buying and Selling for Geron.

How do I buy shares of Geron?

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $5.50.

How big of a company is Geron?

Geron has a market capitalization of $1.01 billion and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,910,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. Geron employs 18 workers across the globe.

How can I contact Geron?

Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]


MarketBeat Community Rating for Geron (NASDAQ GERN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  304 (Vote Outperform)
Underperform Votes:  239 (Vote Underperform)
Total Votes:  543
MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote "Outperform" if you believe GERN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel